Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zilovertamab vedotin - VelosBio

Next Previous
Drug Profile

Zilovertamab vedotin - VelosBio

Alternative Names: MK 2140; VLS 101

Latest Information Update: 01 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme; VelosBio
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diffuse large B cell lymphoma
  • Phase II Bladder cancer; Breast cancer; Chronic lymphocytic leukaemia; Follicular lymphoma; Gastric cancer; Haematological malignancies; Mantle-cell lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Richter's syndrome; Solid tumours
  • No development reported Ewing's sarcoma; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 12 Jun 2025 Efficacy data from a phase II/III Waveline-003 trial presented at the30th Congress of the European Haematology Association (EHA-2025)
  • 30 May 2025 Update adverse events and efficacy data from the phase II/III waveLINE-003 trial in Diffuse large B-cell lymphoma presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 30 May 2025 Efficacy and adverse events data from the phase II/III waveLINE-003 trial in Diffuse large B-cell lymphoma released by Merck Sharp & Dohme

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top